|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.18 USD | -2.30% |
|
0.00% | +41.19% |
| 06-09 | Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases | MT |
| 05-26 | Cartesian Therapeutics, Inc. Announces Executive Changes | CI |
| Market Cap | 306M 269M 247M 231M 435M 29.11B 444M 2.98B 1.15B 14.29B 1.15B 1.12B 49.72B | P/E 2026 * |
-2.51x | P/E 2027 * | -2.72x |
|---|---|---|---|---|---|
| Enterprise Value | 163M 143M 131M 122M 231M 15.46B 236M 1.58B 613M 7.59B 611M 598M 26.42B | EV / Sales 2026 * |
295x | EV / Sales 2027 * | 10.1x |
| Free-Float |
46.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cartesian Therapeutics, Inc.
| 1 day | -2.30% | ||
| Current month | -2.30% | ||
| 1 month | +35.01% | ||
| 3 months | +65.53% | ||
| 6 months | +41.19% | ||
| Current year | +41.19% |
| 1 week | 8.8 |  | 10.62 |
| 1 month | 5.77 | | 11 |
| Current year | 5.6 | | 11 |
| 1 year | 5.6 | | 15.57 |
| 3 years | 5.6 | | 42.6 |
| 5 years | 5.6 | | 42.6 |
| 10 years | 5.6 | | 42.6 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-02 | Fiscal year | 758,001 | 2.8594% | |||
| 04-02 | Fiscal year | 22,740 | - | |||
| 04-02 | Fiscal year | 22,740 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.30% | 0.00% | -2.02% | - | 306M | |
| -2.19% | -2.39% | +68.92% | +123.30% | 57.65B | |
| +0.55% | +17.77% | +80.01% | +100.93% | 55.14B | |
| +0.93% | +3.64% | -11.79% | -12.98% | 23.53B | |
| +0.36% | +4.75% | +6.32% | +407.11% | 23.11B | |
| -1.93% | +11.11% | +34.89% | -7.86% | 18.14B | |
| +0.28% | +5.36% | +36.88% | -30.23% | 16.84B | |
| -0.83% | +5.10% | +22.43% | +182.37% | 13.68B | |
| +0.14% | +9.60% | +33.31% | - | 12.97B | |
| -4.20% | +0.19% | +69.97% | +122.68% | 12.38B | |
| Average | -0.92% | +5.24% | +33.89% | +110.66% | 23.37B | |
| Weighted average by Cap. | -0.68% | +4.62% | +47.54% | +114.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 552K 485K 446K 416K 784K 52.5M 800K 5.37M 2.08M 25.77M 2.07M 2.03M 89.69M | 402K 353K 324K 302K 570K 38.17M 582K 3.9M 1.51M 18.74M 1.51M 1.47M 65.21M |
| Net income | -122M -107M -98.88M -92.14M -174M -11.63B -177M -1.19B -461M -5.71B -459M -449M -19.87B | -131M -115M -106M -98.44M -186M -12.43B -189M -1.27B -492M -6.1B -491M -480M -21.23B |
| Net Debt | -144M -126M -116M -108M -204M -13.64B -208M -1.39B -540M -6.7B -539M -527M -23.31B | -302M -265M -244M -228M -429M -28.72B -438M -2.94B -1.14B -14.1B -1.13B -1.11B -49.07B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/26 | $10.18 | -2.30% | 152,683 |
| 30/06/26 | $10.42 | +8.09% | 535,370 |
| 29/06/26 | $9.640 | +2.34% | 191,870 |
| 26/06/26 | $9.420 | +5.49% | 765,474 |
| 25/06/26 | $8.930 | -7.37% | 265,804 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RNAC Stock
Select your edition
All financial news and data tailored to specific country editions
